Sanofi

14 November 2005 13:32

INTERNATIONELL DIABETESUNDERSÖKNING BELYSER ATT PERSONER MED DIABETES OCH VÅRDGIVARE HAR OLIKA UPPFATTNINGAR OM SJUKDOMEN OCH HUR DEN SKA BEHANDLAS

En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon

10 November 2005 10:19

SANOFI PASTEUR SIGNS CONTRACT WITH FRENCH GOVERNMENT TO PRODUCE PANDEMIC INFLUENZA VACCINE

Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France November 10, 2005 Following discussions which started a few months ago, sanofi pasteur,

25 Oktober 2005 15:35

APPOINTMENT OF JEAN-YVES WESSELY HEAD OF SANOFI-AVENTIS WINTHROP

Paris October 24, 2005- Effective october 2oo5, Jean-Yves Wessely is appointed Senior Vice President in charge of Winthrop, worldwide Generics Activities of sanofi-aventis, based in Paris. Jean-Yves Wessely, MD, brings with him a wealth of more than 25 years of experience in the pharmaceutical industry, as well as an intimate knowledge of Winthrop's key markets, having held several regional a

20 Oktober 2005 15:55

EXUBERA® INHALED INSULIN IMPROVES BLOOD SUGAR LEVELS IN ADULTS WITH TYPE 2 DIABETES BETTER THAN DIABETES PILLS ALONE 1

Paris, 2005-10-20: Adults with type 2 diabetes taking Exubera (insulin human) alone or in combination with diabetes pills achieved significantly greater reductions in blood sugar levels compared to patients taking pills alone, according to a new study published in the October issue of Annals of Internal Medicine. Läs mer i bifogad fil. See attached document.

14 Oktober 2005 14:03

EXUBERA® RECEIVES POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF TYPE 1 + TYPE 2 DIABETES

Paris October 14, 2005 Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of EXUBERA (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes. The proposed therapeutic indication for Exubera is for the treatment of adult pati

21 September 2005 09:33

TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR

MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 Data presented today at the 15th Annual Internati

15 September 2005 13:41

TAXOTERE®-BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv

15 September 2005 08:55

DATA AT EASD SUGGESTS BETTER GLYCAEMIC CONTROL POSSIBLE USING INSULIN GLARGINE OR INSULIN GLULISINE IN TYPE 2 DIABETES

Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv

31 Augusti 2005 09:44

Strong growth in 2005 first half adjusted EPS : up 26.1% at 2.22

Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products

18 Augusti 2005 12:10

Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin

I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel

8 Augusti 2005 13:55

RESOLUTION OF UK PLAVIX® LITIGATION

Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&

8 Augusti 2005 08:55

SANOFI-AVENTIS SELLS ITS INTERESTS IN WACKER-CHEMIE

- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.

Nyhetsarkiv